Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on August 29, 2016. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and a concurrent private placement transaction.
Key Financial Metrics and Transactions
The filing does not report standard operating financial metrics such as revenue, profit, cash flow, or debt levels. The only specific financial data disclosed relates to a capital transaction:
- Private Placement: On August 29, 2016, the company completed a private placement raising $750,000.
- Securities Issued: The transaction involved the sale of 230,769 shares of common stock and 230,769 stock purchase warrants.
- Investor: The securities were purchased by Don M. Bailey, the newly appointed director.
Material Changes
The primary material change reported is the composition of the Board of Directors:
- Resignation: Michael D. West resigned from the Board of Directors.
- Appointment: Don M. Bailey was appointed to fill the vacancy. He will serve on the Audit Committee and the Nominating/Corporate Governance Committee.
- Compensation Structure: Mr. Bailey's compensation includes an annual cash fee of $20,000, meeting fees, and options to purchase 20,000 shares of common stock vesting quarterly over four years.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, revenue outlook, or management commentary regarding future operations. It includes a standard Forward-Looking Statements disclaimer, noting that actual results may differ materially from anticipated results due to risk factors detailed in the company's Form 10-K and Form 10-Q filings. The filing does not disclose any new contingencies or unusual items beyond the director appointment and capital raise.
Investor Verification Checklist
- Verify the impact of the $750,000 private placement on the company's current cash position and dilution.
- Review the full Form 10-K and 10-Q filings to assess the "Risk Factors" referenced in the forward-looking statements.
- Confirm the vesting schedule and exercise terms for the 20,000 stock options granted to the new director.
- Check subsequent filings for any updates regarding the resignation of Michael D. West or the strategic rationale for the new board composition.